NO20090583L - Terapi for alfa-galaktosidase A-mangel - Google Patents

Terapi for alfa-galaktosidase A-mangel

Info

Publication number: NO20090583L
Authority: NO; Norway
Prior art keywords: galactosidase; therapy; deficiency; alpha; sample
Prior art date: 1996-09-13

Application number

NO20090583A

Other languages

English (en)

Other versions

NO330687B1 (no

Inventor

Richard F Selden

Marianne Borowski

Francis P Gillespie

Carol M Kinoshita

Douglas A Treco

Melanie D Williams

Original Assignee

Shire Human Genetic Therapies

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-13

Filing date

2009-02-06

Publication date

1999-05-10

1999-05-10 Publication of NO20090583L publication Critical patent/NO20090583L/no

2009-02-06 Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies

2011-06-06 Publication of NO330687B1 publication Critical patent/NO330687B1/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Cardiology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Hematology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
General Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Heart & Thoracic Surgery (AREA)
Microbiology (AREA)
Endocrinology (AREA)
Biotechnology (AREA)
Diabetes (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Biophysics (AREA)
Hospice & Palliative Care (AREA)
Toxicology (AREA)
Rheumatology (AREA)

NO20090583A 1996-09-13 2009-02-06 Fremgangsmate for rensing av human alfa-galaktosidase A NO330687B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US71261496A	1996-09-13	1996-09-13
PCT/US1997/016603 WO1998011206A2 (en)	1996-09-13	1997-09-12	THERAPY FOR α-GALACTOSIDASE A DEFICIENCY

Publications (2)

Publication Number	Publication Date
NO20090583L true NO20090583L (no)	1999-05-10
NO330687B1 NO330687B1 (no)	2011-06-06

Family

ID=24862863

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
NO19991225A NO328443B1 (no)	1996-09-13	1999-03-12	DNA-molekyl, ekspresjonskonstruksjon, dyrket human celle, kloncellestamme, kloncellelinje, protein, fremgangsmate for fremstilling av glykosylert human alfa-galaktosidase A og human alfa-galaktosidase A samt anvendelse av en human celle som er genetisk modifisert.
NO20090583A NO330687B1 (no)	1996-09-13	2009-02-06	Fremgangsmate for rensing av human alfa-galaktosidase A
NO20110496A NO340408B1 (no)	1996-09-13	2011-03-31	Fremgangsmåte for å produsere humant alfa-galaktosidase A, og farmasøytisk preparat
NO20141168A NO20141168L (no)	1996-09-13	2014-09-29	Fremgangsmåte for rensing av human alfa-galaktosidase A fra en prøve

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
NO19991225A NO328443B1 (no)	1996-09-13	1999-03-12	DNA-molekyl, ekspresjonskonstruksjon, dyrket human celle, kloncellestamme, kloncellelinje, protein, fremgangsmate for fremstilling av glykosylert human alfa-galaktosidase A og human alfa-galaktosidase A samt anvendelse av en human celle som er genetisk modifisert.

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
NO20110496A NO340408B1 (no)	1996-09-13	2011-03-31	Fremgangsmåte for å produsere humant alfa-galaktosidase A, og farmasøytisk preparat
NO20141168A NO20141168L (no)	1996-09-13	2014-09-29	Fremgangsmåte for rensing av human alfa-galaktosidase A fra en prøve

Country Status (21)

Country	Link
EP (4)	EP0935651B1 (no)
JP (7)	JP4001925B2 (no)
KR (2)	KR100547402B1 (no)
CN (1)	CN1268741C (no)
AT (1)	ATE286120T1 (no)
AU (1)	AU4424497A (no)
CA (1)	CA2265464C (no)
DE (1)	DE69732129T2 (no)
DK (2)	DK1538202T3 (no)
ES (3)	ES2234032T3 (no)
HK (3)	HK1022173A1 (no)
HU (2)	HU230275B1 (no)
IL (2)	IL128960A (no)
MX (1)	MX340738B (no)
NO (4)	NO328443B1 (no)
NZ (2)	NZ334721A (no)
PL (1)	PL190041B1 (no)
PT (1)	PT1538202E (no)
RU (1)	RU2179034C2 (no)
TW (1)	TW585919B (no)
WO (1)	WO1998011206A2 (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6458574B1 (en) *	1996-09-12	2002-10-01	Transkaryotic Therapies, Inc.	Treatment of a α-galactosidase a deficiency
US6083725A (en)	1996-09-13	2000-07-04	Transkaryotic Therapies, Inc.	Tranfected human cells expressing human α-galactosidase A protein
DE69835367T2 (de) *	1997-10-29	2007-08-02	Genzyme Corp., Framingham	Gentherapie für gaucher-krankheit
EP1658857A1 (en) *	1997-10-29	2006-05-24	Genzyme Corporation	Compositions and methods for treating lysosomal storage disease
US6274597B1 (en)	1998-06-01	2001-08-14	Mount Sinai School Of Medicine Of New York University	Method of enhancing lysosomal α-Galactosidase A
AU2016250357B2 (en) *	1999-03-11	2018-11-01	Shire Human Genetic Therapies, Inc.	Treatment of alpha-Galactosidase A deficiency
AU2004242550B2 (en) *	1999-03-11	2008-04-03	Shire Human Genetic Therapies, Inc.	Treatment of alpha-Galactosidase A deficiency
AU2012241170B2 (en) *	1999-03-11	2016-07-28	Shire Human Genetic Therapies, Inc.	Treatment of alpha-Galactosidase A deficiency
WO2002064799A2 (en)	1999-09-28	2002-08-22	Transkaryotic Therapies, Inc.	Optimized messenger rna
EP2275559A3 (en) *	1999-09-28	2011-03-23	Shire Human Genetic Therapies, Inc.	Optimized messenger RNA
WO2001042442A2 (en)	1999-12-10	2001-06-14	Cytos Biotechnology Ag	Activation of endogenous genes by genomic introduction of a replicon
CA2398995C (en)	2000-02-04	2014-09-23	Children's Hospital Research Foundation	Lipid hydrolysis therapy for atherosclerosis and related diseases
US20020095135A1 (en)	2000-06-19	2002-07-18	David Meeker	Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7138262B1 (en) *	2000-08-18	2006-11-21	Shire Human Genetic Therapies, Inc.	High mannose proteins and methods of making high mannose proteins
IL140110A0 (en)	2000-12-05	2002-02-10	Applied Research Systems	Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
EP2361631A1 (en)	2002-04-25	2011-08-31	Shire Human Genetic Therapies, Inc.	Treatment of alpha-galactosidase a deficiency
WO2004064750A2 (en)	2003-01-22	2004-08-05	Duke University	Improved constructs for expressing lysosomal polypeptides
JP4368925B2 (ja)	2005-11-18	2009-11-18	財団法人東京都医学研究機構	基質特異性を変換した新規高機能酵素
AR059089A1 (es) *	2006-01-20	2008-03-12	Genzyme Corp	Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
EP2361613B1 (en)	2006-02-07	2020-08-12	Shire Human Genetic Therapies, Inc.	Stabilized compositions of proteins having a free thiol moiety
CA2641359C (en)	2006-02-09	2022-10-04	Genzyme Corporation	Slow intraventricular delivery
JP5507242B2 (ja) *	2007-05-18	2014-05-28	公益財団法人東京都医学総合研究所	酵素補充療法用医薬組成物
CN103432566A (zh)	2008-12-16	2013-12-11	建新公司	寡糖-蛋白缀合物
PL3354277T3 (pl)	2009-07-28	2021-12-13	Takeda Pharmaceutical Company Limited	Kompozycje i sposoby leczenia choroby gauchera
PL3205351T3 (pl)	2010-04-23	2023-08-28	Alexion Pharmaceuticals, Inc.	Enzym na lizosomalną chorobę spichrzeniową
EP2595651B1 (en)	2010-07-19	2017-03-29	Shire Human Genetic Therapies, Inc.	Mannose receptor c type 1 (mrc1) codon optimized cell line and uses thereof
SG188456A1 (en)	2010-09-09	2013-04-30	Synageva Biopharma Corp	Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
KR20140006037A (ko)	2011-02-15	2014-01-15	시나게바 바이오파르마, 코포레이션	리소좀의 산 리파제 결핍을 치료하는 방법들
US20140301977A1 (en) *	2011-11-02	2014-10-09	Genentech, Inc.	Overload and elute chromatography
CN104519905A (zh)	2012-03-02	2015-04-15	夏尔人类遗传性治疗公司	用于治疗iii型戈谢病的组合物和方法
BR112014032919B1 (pt) *	2012-06-29	2023-03-28	Universitat De Barcelona	Conjugado e seu método de produção, lipossomas, uso e método de produção dos mesmos, bem como composição farmacêutica
JP6226435B2 (ja) *	2012-07-26	2017-11-08	Ｊｃｒファーマ株式会社	組換えヒトα−ガラクトシダーゼＡの製造方法
WO2014016873A1 (en) *	2012-07-26	2014-01-30	Jcr Pharmaceuticals Co., Ltd.	Method for production of recombinant human alpha-galactosidase a
AU2013334644B2 (en)	2012-10-24	2018-07-12	Genzyme Corporation	Elution of biomolecules from multi-modal resins using mes and mops as mobile phase modifiers
TWI642782B (zh) *	2013-10-23	2018-12-01	健臻公司	重組醣蛋白及其用途
US20170360900A1 (en) *	2014-12-22	2017-12-21	Codexis, Inc.	Human alpha-galactosidase variants
WO2016116966A1 (en)	2015-01-22	2016-07-28	Jcr Pharmaceuticals Co., Ltd.	Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
GB201508025D0 (en) *	2015-05-11	2015-06-24	Ucl Business Plc	Fabry disease gene therapy
EP3646899B1 (en)	2017-06-30	2024-07-31	FUJIFILM Corporation	Lysosomal storage disease treatment agent
ES2716305B2 (es)	2017-12-11	2019-11-27	Fund Biomedica Galicia Sur	Uso de chaperonas farmacologicas para el tratamiento de enfermedades de deposito lisosomal
BR112021011750A2 (pt)	2018-12-20	2021-08-31	Codexis, Inc.	Alfa-galactosidase a recombinante e/ou fragmento de alfa-galactosidase a recombinante, composição, sequência de polinucleotídeo recombinante, vetor de expressão, célula hospedeira, métodos para produzir uma variante de alfa-galactosidase a e para tratar e/ou prevenir os sintomas da doença de fabry, composição farmacêutica, e, uso das composições
CN111308095A (zh) *	2020-03-04	2020-06-19	北京师范大学	用于诊断前列腺癌的尿液蛋白标记物
TW202423959A (zh) *	2022-08-24	2024-06-16	美商步行魚醫療公司	用於治療法布瑞氏症(fabry disease)之組成物及方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2619719B1 (fr) *	1987-09-01	1991-05-10	Sanofi Sa	Procede d'obtention d'interleukine-2 a partir de cellules eucaryotes, vecteurs necessaires a sa mise en oeuvre et lignees cellulaires hautement productrices
FI96121C (fi) *	1987-10-02	1996-05-10	Zymogenetics Inc	DNA-rakenne ja menetelmä heterologisen proteiinin tuottamiseksi
US5179023A (en)	1989-03-24	1993-01-12	Research Corporation Technologies, Inc.	Recombinant α-galactosidase a therapy for Fabry disease
EP0463109A4 (en) *	1989-03-24	1992-11-19	Research Corporation Technologies, Inc.	Recombinant alpha-galactosidase, a therapy for fabry disease
NZ234453A (en) *	1989-07-13	1993-01-27	Sanofi Sa	Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
IL95330A0 (en) *	1989-08-11	1991-06-30	Lilly Co Eli	Expression of a functional insect specific toxin gene in mammalian cells
CA2092823A1 (en) *	1990-09-28	1992-03-29	Barry D. Greenberg	Transgenic animals with alzheimer's amyloid precursor gene
US5356804A (en)	1990-10-24	1994-10-18	Mount Sinai School Of Medicine Of The City Of New York	Cloning and expression of biologically active human α-galactosidase A
US5401650A (en) *	1990-10-24	1995-03-28	The Mount Sinai School Of Medicine Of The City University Of New York	Cloning and expression of biologically active α-galactosidase A
WO1993008292A1 (en) *	1991-10-16	1993-04-29	Agracetus, Inc.	Particle-mediated transformation of animal somatic cells
US5641670A (en)	1991-11-05	1997-06-24	Transkaryotic Therapies, Inc.	Protein production and protein delivery
PT101031B (pt) *	1991-11-05	2002-07-31	Transkaryotic Therapies Inc	Processo para o fornecimento de proteinas por terapia genetica
SE9300105D0 (sv) *	1993-01-15	1993-01-15	Kabi Pharmacia Ab	Stable protein solution
CA2166488A1 (en) *	1993-07-02	1995-01-12	Marian N. Marra	Glycosylated and non-glycosylated bactericidal/permeability increasing proteins, and methods for producing same
NZ329619A (en)	1994-01-13	1999-09-29	Rogosin Inst	Use of macroencapsulated secretory cells in agarose coated collagen gel material to treat diseases related to secretory cell failure
JP2984552B2 (ja) *	1994-09-02	1999-11-29	大和化成株式会社	ラッカーゼおよびその生産方法
US5541087A (en) *	1994-09-14	1996-07-30	Fuji Immunopharmaceuticals Corporation	Expression and export technology of proteins as immunofusins
JPH08196293A (ja) *	1995-01-25	1996-08-06	Mitsui Toatsu Chem Inc	タンパク質の製造方法
AU691410B2 (en) *	1995-02-15	1998-05-14	Amgen, Inc.	MPL ligand analogs

1997
- 1997-09-12 RU RU99107287/14A patent/RU2179034C2/ru active
- 1997-09-12 EP EP97942567A patent/EP0935651B1/en not_active Expired - Lifetime
- 1997-09-12 IL IL128960A patent/IL128960A/en not_active IP Right Cessation
- 1997-09-12 NZ NZ334721A patent/NZ334721A/xx not_active IP Right Cessation
- 1997-09-12 KR KR1019997002088A patent/KR100547402B1/ko not_active IP Right Cessation
- 1997-09-12 MX MX2014010892A patent/MX340738B/es unknown
- 1997-09-12 AU AU44244/97A patent/AU4424497A/en not_active Abandoned
- 1997-09-12 AT AT97942567T patent/ATE286120T1/de active
- 1997-09-12 KR KR1020057011793A patent/KR20050084473A/ko not_active Application Discontinuation
- 1997-09-12 NZ NZ506214A patent/NZ506214A/xx not_active IP Right Cessation
- 1997-09-12 ES ES97942567T patent/ES2234032T3/es not_active Expired - Lifetime
- 1997-09-12 CA CA002265464A patent/CA2265464C/en not_active Expired - Lifetime
- 1997-09-12 DK DK04030107.9T patent/DK1538202T3/en active
- 1997-09-12 PT PT40301079T patent/PT1538202E/pt unknown
- 1997-09-12 HU HU1000445A patent/HU230275B1/hu unknown
- 1997-09-12 EP EP10181991A patent/EP2327775A3/en not_active Withdrawn
- 1997-09-12 PL PL97332188A patent/PL190041B1/pl unknown
- 1997-09-12 JP JP51400498A patent/JP4001925B2/ja not_active Expired - Lifetime
- 1997-09-12 EP EP04030107.9A patent/EP1538202B1/en not_active Expired - Lifetime
- 1997-09-12 ES ES04030107.9T patent/ES2458292T3/es not_active Expired - Lifetime
- 1997-09-12 DE DE69732129T patent/DE69732129T2/de not_active Expired - Lifetime
- 1997-09-12 DK DK10181859.9T patent/DK2374876T3/en active
- 1997-09-12 EP EP10181859.9A patent/EP2374876B1/en not_active Expired - Lifetime
- 1997-09-12 CN CNB97197909XA patent/CN1268741C/zh not_active Expired - Lifetime
- 1997-09-12 WO PCT/US1997/016603 patent/WO1998011206A2/en active Application Filing
- 1997-09-12 ES ES10181859.9T patent/ES2581828T3/es not_active Expired - Lifetime
- 1997-09-12 HU HU9904666A patent/HU227189B1/hu unknown
- 1997-09-13 TW TW086113342A patent/TW585919B/zh not_active IP Right Cessation
1999
- 1999-03-12 NO NO19991225A patent/NO328443B1/no not_active IP Right Cessation
2000
- 2000-02-23 HK HK00101063A patent/HK1022173A1/xx not_active IP Right Cessation
2005
- 2005-09-05 HK HK12102808.4A patent/HK1162580A1/zh not_active IP Right Cessation
- 2005-09-05 HK HK05107760.8A patent/HK1074058A1/xx not_active IP Right Cessation
2006
- 2006-07-18 JP JP2006195854A patent/JP4313381B2/ja not_active Expired - Lifetime
2007
- 2007-06-13 JP JP2007155943A patent/JP4313405B2/ja not_active Expired - Lifetime
- 2007-07-16 IL IL184637A patent/IL184637A/en not_active IP Right Cessation
2008
- 2008-11-26 JP JP2008300426A patent/JP2009060918A/ja not_active Withdrawn
- 2008-11-26 JP JP2008300335A patent/JP5590788B2/ja not_active Expired - Lifetime
2009
- 2009-02-06 NO NO20090583A patent/NO330687B1/no not_active IP Right Cessation
2011
- 2011-03-31 NO NO20110496A patent/NO340408B1/no not_active IP Right Cessation
- 2011-09-06 JP JP2011193635A patent/JP2012019793A/ja not_active Withdrawn
2014
- 2014-09-29 NO NO20141168A patent/NO20141168L/no not_active Application Discontinuation
- 2014-10-15 JP JP2014210566A patent/JP2015044830A/ja active Pending

Also Published As

Publication number	Publication date
HUP9904666A3 (en)	2001-09-28
IL128960A0 (en)	2000-02-17
EP0935651B1 (en)	2004-12-29
EP2327775A2 (en)	2011-06-01
EP2374876B1 (en)	2016-04-13
HU227189B1 (en)	2010-10-28
ES2581828T3 (es)	2016-09-07
PL332188A1 (en)	1999-08-30
EP1538202A3 (en)	2007-05-30
WO1998011206A3 (en)	1998-08-13
NO20110496L (no)	1999-05-10
MX340738B (es)	2016-07-22
KR20000036078A (ko)	2000-06-26
IL184637A (en)	2015-07-30
EP1538202B1 (en)	2014-01-22
JP2007289201A (ja)	2007-11-08
NO991225D0 (no)	1999-03-12
PT1538202E (pt)	2014-04-22
JP4313381B2 (ja)	2009-08-12
CN1268741C (zh)	2006-08-09
NO991225L (no)	1999-05-10
TW585919B (en)	2004-05-01
EP1538202A2 (en)	2005-06-08
CA2265464C (en)	2007-06-26
EP0935651A2 (en)	1999-08-18
CA2265464A1 (en)	1998-03-19
ES2234032T3 (es)	2005-06-16
DE69732129T2 (de)	2005-12-08
EP2374876A3 (en)	2012-10-24
HK1162580A1 (zh)	2012-08-31
HU230275B1 (hu)	2015-11-30
NO328443B1 (no)	2010-02-22
IL184637A0 (en)	2009-09-22
EP2327775A3 (en)	2012-10-24
JP4313405B2 (ja)	2009-08-12
JP5590788B2 (ja)	2014-09-17
NZ334721A (en)	2001-01-26
JP2009060918A (ja)	2009-03-26
HU1000445D0 (en)	2010-11-29
NZ506214A (en)	2002-11-26
IL128960A (en)	2007-10-31
JP2007000145A (ja)	2007-01-11
JP2012019793A (ja)	2012-02-02
NO340408B1 (no)	2017-04-18
NO20141168L (no)	1999-05-10
JP4001925B2 (ja)	2007-10-31
JP2001504324A (ja)	2001-04-03
JP2009102321A (ja)	2009-05-14
DK1538202T3 (en)	2014-03-24
EP2374876A2 (en)	2011-10-12
PL190041B1 (pl)	2005-10-31
RU2179034C2 (ru)	2002-02-10
HK1074058A1 (en)	2005-10-28
KR20050084473A (ko)	2005-08-26
JP2015044830A (ja)	2015-03-12
HU9904666A (en)	2000-05-28
CN1230220A (zh)	1999-09-29
KR100547402B1 (ko)	2006-02-01
DE69732129D1 (de)	2005-02-03
NO330687B1 (no)	2011-06-06
ATE286120T1 (de)	2005-01-15
AU4424497A (en)	1998-04-02
WO1998011206A2 (en)	1998-03-19
ES2458292T3 (es)	2014-04-30
DK2374876T3 (en)	2016-05-30
HK1022173A1 (en)	2000-07-28

Publication	Publication Date	Title
NO20090583L (no)	1999-05-10	Terapi for alfa-galaktosidase A-mangel
ID30373A (id)	1997-01-23	PARAHERKUAMIDA ANTIPARASIT (Pecahan P-962086)
DE69738979D1 (de)	2008-10-23	Prozesssteuerungssystem
KR950700779A (ko)	1995-02-20	단백질의 정제방법(Protein purification)
IL122718A0 (en)	1998-08-16	Methods for treating diabetes
DE69612991D1 (de)	2001-06-28	System zur bearbeitung von selbstmodifizierendem kode
FR2700213B1 (fr)	1995-03-24	Ensemble de guidage.
ITTO960392A0 (it)	1996-05-13	Analizzatore ottico.
FI99108B (fi)	1997-06-30	Menetelmä hissin ohjaamiseksi
FI953370A0 (fi)	1995-07-07	Menetelmä NDIR-mittalaitteen lyhyen Fabry-Perot inMenetelmä NDIR-mittalaitteen lyhyen Fabry-Perot interferometrin ohjaamiseksi terferometrin ohjaamiseksi
FI941522L (fi)	1994-10-03	Menetelmä hemoglobiiniadditiotuotteiden määrittämiseksi
PT1027339E (pt)	2004-05-31	Metodo e reagentes para a n-alquilacao de ureidos
DK0638068T3 (da)	1999-11-22	Fremgangsmåde til fremstilling af (S)-3-amino-1-substitueret-pyrrolidiner
NO982911D0 (no)	1998-06-22	FremgangsmÕte for behandling av depresjon
AU662084B2 (en)	1995-08-17	Process for reactivating purified membrane proteins
EP0626164A3 (en)	1995-10-18	Control system for hydromassage baths.
EP0609903A3 (en)	1997-05-02	Program language compiling system.
IT236919Y1 (it)	2000-08-31	Centralina c.p.l. per ascensori
KR970048912U (ko)	1997-08-12	보행기의 지지프레임 가이드장치
SE9604502D0 (sv)	1996-12-06	Förfarande för blodmikrospektralanalys
MD676F1 (ro)	1997-02-28	Metoda de tratament al rinosinuzitelor Method for treatment of the rhinosinusitis
IT1282168B1 (it)	1998-03-16	Apparecchiatura per timbrare pelli.
SE9502125D0 (sv)	1995-06-12	Behandlingsförfarande för trävirke
ITTO930166A0 (it)	1993-03-10	Procedimento per il trattamento di flussi reflui della produzione di n-fosfonometilglicina.
NL1002496A1 (nl)	1996-07-11	Loopwagen.

Legal Events

Date	Code	Title	Description
2017-10-09	MK1K	Patent expired